BioSpace News Archive

Novus Therapeutics announced that its Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet its primary endpoint.

When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.

U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn recently gave a speech to the Alliance for a Stronger FDA. In it, he suggested that some of the changes forced on the agency by the COVID-19 pandemic are likely to become permanent.

Emergent BioSolutions, a contract development and manufacturing organization, announced it had signed a public-private partnership under Operation Warp Speed worth about $628 million.

CSL Behring has developed a number of strategies to address COVID-19, the disease caused by the novel coronavirus that originated in China and spread across the globe in a matter of months.

This morning, BMS said Zeposia achieved positive topline results in the Phase III True North clinical study in patients with moderate to severe ulcerative colitis.

Pfizer has its eye on supporting innovation in the biotech industry to support small and medium-sized companies working in indications that fall under Pfizer’s core areas of focus.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present at the 2020 Virtual Investor Summit being held on June 9-12, 2020. Details of the presentation are as follo

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (“Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (“COVID-19”) outbreak, and government-recommended and required limits on public gatherings. Holding the Annual Meeting online will also protect the health and safety of the Company’s stoc